Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Who May Be Eligible (Plain English)

Who May Qualify: - Age ≥ 18 years and ≤ 65 years - Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL) - Any stage of disease (nodal or extra-nodal), with or without B symptoms - Scheduled to receive standard systemic treatment (R-CHOP) - You should be able to carry out daily activities with 0 level of ability (ECOG 0)-2 - Baseline normal: - Complete blood count (CBC) - Hepatitis viral markers - Liver and renal function tests - Urine analysis - Echocardiogram - Additional investigations to exclude current infection if clinically indicated Who Should NOT Join This Trial: - History of other concurrent or previous malignancies - Relapsed or refractory DLBCL - Uncontrolled comorbid conditions that may interfere with study participation, including: - Diabetes mellitus - autoimmune conditions (where your immune system attacks your own body)s - Active infections - Chronic inflammatory diseases - Cardiac dysfunction - Liver cell failure - Pregnant females Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age ≥ 18 years and ≤ 65 years * Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL) * Any stage of disease (nodal or extra-nodal), with or without B symptoms * Scheduled to receive standard systemic treatment (R-CHOP) * ECOG performance status 0-2 * Baseline normal: * Complete blood count (CBC) * Hepatitis viral markers * Liver and renal function tests * Urine analysis * Echocardiogram * Additional investigations to exclude current infection if clinically indicated Exclusion Criteria: * History of other concurrent or previous malignancies * Relapsed or refractory DLBCL * Uncontrolled comorbid conditions that may interfere with study participation, including: * Diabetes mellitus * Autoimmune diseases * Active infections * Chronic inflammatory diseases * Cardiac dysfunction * Liver cell failure * Pregnant females

Treatments Being Tested

DRUG

Observational Assessment of Standard R-CHOP Treatment

Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.

Locations (1)

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University
Cairo, Cairo Governorate, Egypt